Back to Search
Start Over
More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.
- Source :
- Annals of Hematology; Oct2023, Vol. 102 Issue 10, p2943-2945, 3p
- Publication Year :
- 2023
-
Abstract
- Also, there were no significant differences between patients with either 2-5% or 5-20% CPCs and those with >= 20% CPCs in PFS and OS ( I P i > 0.05). Compared to patients with < 2% CPCs, median PFS and OS of patients with 2-20% CPCs were 11.2 months (vs 18.8 months, I P i = 0.0001; Fig. [Extracted from the article]
- Subjects :
- MULTIPLE myeloma
PLASMA cells
PLASMA cell leukemia
PLASMACYTOMA
Subjects
Details
- Language :
- English
- ISSN :
- 09395555
- Volume :
- 102
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Annals of Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 171844563
- Full Text :
- https://doi.org/10.1007/s00277-023-05362-8